Another 5 years of dominance: Oncology, immunology will extend their lead as pharma's top fields through 2025

Cancer and autoimmune diseases aren’t going anywhere. And so the scramble to develop next-gen treatments rages on.

As a result, global spending on oncology and immunology medicines will significantly grow through 2025 as those treatment areas widen their lead as healthcare’s top two fields, the IQVIA Institute for Human Data Science found in a recent report.